Skip to main content

Table 3 Clinical benefit rate of ASI with diffident type of vaccines in advanced CRC, post hoc explorative analysis

From: Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review

vaccine clinical benefit rate
autologous tumor cell 20/70(28.6%)
Peptide vaccine 45/142(31.7%)
Viral vector vaccine 46/163(28.2%)
DC vaccine 30/134(22.4%)